Researcher.Life Logo

Hematology : Impact Factor & More

eISSN: 1607-8454pISSN: 1024-5332
JournalOpen Access

Key Metrics

CiteScore
3.2
H-Index
46
SJR
Q3Hematology
SNIP
0.93
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Hematology

Hematology Journal Specifications

Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Continuous publication
Article Processing ChargesGBP 2085
Publication Time19
Editorial Review ProcessDouble anonymous peer review
General Details
LanguageEnglish
Society/Institute/SponsorInternational Society of Hematology
FrequencyContinuous publication
Publication Start Year1996
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 19
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessDouble anonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Hematology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Hematology

Correlation between epigenetic modifier gene mutations and prognosis of patients with acute lymphoblastic leukemia: a systematic review and meta-analysis
  • 31 Dec 2026
  • Hematology
Cyclosporine A improves survival in lower-risk hypoplastic myelodysplastic syndromes: a single-center retrospective study from China
  • 31 Dec 2026
  • Hematology
Severe hemolysis flare of refractory autoimmune hemolytic anemia with positive complement component C3d responsive to Iptacopan with cyclophosphamide and prednisone: a case report
  • 31 Dec 2025
  • Hematology
Comparative analysis of primary immune thrombocytopenia and immune thrombocytopenia secondary to connective tissue diseases
  • 31 Dec 2025
  • Hematology
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registry
  • 31 Dec 2025
  • Hematology
NAT10 contributes to the progression of multiple myeloma through ac4C modification of GPR37
  • 31 Dec 2025
  • Hematology
Correlation between epigenetic modifier gene mutations and prognosis of patients with acute lymphoblastic leukemia: a systematic review and meta-analysis
  • 31 Dec 2026
  • Hematology
Cyclosporine A improves survival in lower-risk hypoplastic myelodysplastic syndromes: a single-center retrospective study from China
  • 31 Dec 2026
  • Hematology
Severe hemolysis flare of refractory autoimmune hemolytic anemia with positive complement component C3d responsive to Iptacopan with cyclophosphamide and prednisone: a case report
  • 31 Dec 2025
  • Hematology
Comparative analysis of primary immune thrombocytopenia and immune thrombocytopenia secondary to connective tissue diseases
  • 31 Dec 2025
  • Hematology
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registry
  • 31 Dec 2025
  • Hematology
NAT10 contributes to the progression of multiple myeloma through ac4C modification of GPR37
  • 31 Dec 2025
  • Hematology

FAQs on Hematology